Psoriasis is a chronic skin condition with significant unmet medical needs, characterized by high levels of reactive oxygen species (ROS) and accompanying oxidative stress. In this study, we developed a novel single-atom iron nanozyme (Fe-N3), designed to mimic natural antioxidant enzymes, for the effective treatment of psoriasis. By optimizing the local coordination environment of Fe atoms, Fe-N3 demonstrated superior superoxide dismutase (SOD), catalase (CAT), ascorbate peroxidase (APx), and glutathione peroxidase (GPx)-like activities compared to Fe-N4. These properties enable efficient ROS scavenging and oxidative stress alleviation. Theoretical analyses revealed that Fe-N3 possesses lower energy barriers for ROS decomposition, explaining its superior catalytic performance. Furthermore, in vitro and in vivo experiments have demonstrated that Fe-N3 nanozyme exhibited remarkable therapeutic effects with extremely low cytotoxicity, effectively inhibiting pathological epidermal proliferation, downregulating key inflammatory factors, and reducing the expression levels of psoriasis-associated pathway proteins. This work highlights the promise of single-atom nanozymes in the curing of inflammatory skin diseases, advancing the transformative role of nanotechnology in biomedicine.
Cutaneous squamous cell carcinoma (cSCC) is a common and aggressive skin cancer, with treatment options for advanced stages often limited by chemoresistance. Here, we observe a positive correlation between PHF20 expression and the malignancy and tumor grade of cSCC. Functional studies suggest that PHF20 promotes oncogenic phenotypes, including proliferation, invasion, and epithelial-mesenchymal transition. Notably, PHF20 depletion appears to sensitize cSCC cells to chemotherapeutic agents. Mechanistically, we show that PHF20 interacts with and promotes the ubiquitin-mediated degradation of GAS7. This downregulation of GAS7 is associated with nuclear F-actin assembly, a process that has been implicated in DNA damage repair (DDR). Consequently, PHF20 loss stabilizes GAS7, enhances nuclear F-actin assembly, and is accompanied by increased DNA damage accumulation. These in vitro findings were corroborated in vivo, where PHF20 knockdown suppressed tumor growth and increased DNA damage. Together, PHF20 may contribute to the regulation of DDR and chemotherapeutic response, highlighting its potential as a therapeutic target in poorly differentiated cSCC.